Atrial Fibrillation Trial, Recruiting NCT06249347 Sponsor: Second Affiliated Hospital of Wenzhou Medical University Condition: Atrial Fibrillation
Back to Atrial Fibrillation

Atrial Fibrillation Trial, Recruiting

NCT06249347
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who are older than 18 years of age
  • People who have persistent atrial fibrillation (an irregular heart rhythm that has lasted more than 7 days)
  • People whose heart condition and health history place them at a moderate-to-high risk of stroke, as measured by a standard medical scoring tool called CHA2DS2-VASc (score of 2 or higher)
  • People who meet at least one of the following: long-term blood thinning medication is not considered suitable for them; they experienced a stroke or blood clot even while taking blood thinning medication as directed; their risk of bleeding is rated as high by a standard medical scoring tool called HAS-BLED (score of 3 or higher); or they are unwilling to take long-term blood thinning medication

Who may not be able to join:

  • People who have previously had a procedure to treat atrial fibrillation by targeting the heart's electrical pathways (ablation)
  • People whose heart ultrasound shows that a specific chamber of the heart (the left atrium) is larger than 60 mm across
  • People whose persistent atrial fibrillation has lasted longer than 10 years
  • People who are already scheduled for a heart surgery
  • People who have a blood clot or other structural problem in the upper left chamber of the heart that would prevent the procedure from being safely performed (confirm with trial site)
  • People whose life expectancy is less than 1 year

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 8 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Yue-chun Li, MD, Second Affiliated Hospital of Wenzhou Medical University

Phone: +86-0577-8567-6610

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Second Affiliated Hospital of Wenzhou Medical University
Registry
ClinicalTrials.gov
Start date
28 January 2024
Est. completion
31 December 2026

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Recurrence of atrial arrhythmia after a single ablation procedure.

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 8 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov